Radiation modality denied? We cite ASTRO Model Policies, NCCN, and the pivotal trial data they ignored.

Why radiation oncology denials hinge on modality, not necessity

Insurers rarely deny "radiation therapy." They deny the specific modality — proton beam therapy when photon would do, SBRT when conventional fractionation is on policy, brachytherapy when EBRT alone has been authorized, IMRT when 3D-CRT can theoretically deliver dose, MRI-LINAC when CBCT-IGRT is on the contracted list. The clinical reality is that each modality exists because dose, OAR-sparing, geometric precision, or anatomic adaptation is fundamentally different — and the literature makes that case clearly. Successful appeals close the gap between what the insurer's medical-necessity reviewer sees on the policy bulletin and what the radiation oncologist sees on the treatment plan.

The good news is that radiation oncology has unusually authoritative consensus documents. ASTRO Clinical Practice Guidelines, the ASTRO Model Policy on Proton Beam Therapy, NCCN, the ABS Consensus Statements, and the AAPM Task Group reports collectively cover every modality decision an insurer is likely to challenge. When a denial cites "experimental" or "not medically necessary," the appeal lifts the controlling guideline, demonstrates the patient meets it, and asks the insurer to justify departing from its own medical policy.

The denial categories you'll actually see

Across thousands of radiation-oncology denials, six reasons account for ~90% of all rejections:

1. "Proton beam is investigational outside Group 1 indications" — most common adult proton denial; the insurer has narrowed Group 1 (ocular, skull-base chordoma/chondrosarcoma, paraspinal, pediatric, hepatocellular failing photon constraints, AVM, re-irradiation) and rejects everything else.

2. "Prostate SBRT is experimental" — still appears despite PACE-B and HYPO-RT-PC; usually a documentation problem rather than a policy problem.

3. "Brachytherapy not medically necessary" — most often LDR or HDR boost for high-risk prostate, or APBI brachytherapy for early breast.

4. "IMRT not medically necessary; 3D-CRT sufficient" — the insurer asks for a DVH comparison the practice didn't submit.

5. "Re-irradiation experimental" — cumulative EQD2 must be within consensus thresholds and the case must be defended on toxicity grounds.

6. "Documentation insufficient" — almost always a missing tumor-board note, missing comparative dosimetry, or unstated NCCN risk group.

Each one has a controlled counter — and each counter rests on a real, name-able document.

Proton beam: ASTRO Model Policy is the lever

The ASTRO Model Policy on Proton Beam Therapy (most recent 2024 update) is the single most important document for adult proton appeals because it is the document insurers' own medical policies copy from. UnitedHealthcare's, Aetna's, Cigna's, and Anthem's proton policies all explicitly reference ASTRO Group 1 / Group 2.

Group 1 (covered without comparative dosimetry):

• Pediatric solid tumors (medulloblastoma, craniopharyngioma, ependymoma, Ewing, rhabdomyosarcoma, pineoblastoma, retinoblastoma).
• Ocular tumors including uveal melanoma (the long-standing on-label proton indication).
• Chordoma and chondrosarcoma at skull-base or paraspinal.
• Hepatocellular carcinoma when photon plan cannot meet liver dose constraints.
• Re-irradiation in previously treated fields.
• Selected head-and-neck and base-of-tongue cases meeting OAR criteria.
• Arteriovenous malformations near critical structures.

If your diagnosis is on Group 1, the appeal is mechanical: cite ASTRO Model Policy 2024 (most recent update) section, name the indication, attach the imaging that confirms it, and stop. The insurer's own policy mirrors the document.

Group 2 (case-by-case with comparative dosimetry):

For any adult diagnosis not in Group 1 — non-skull-base head and neck, esophageal, lung, mediastinal lymphoma, breast (especially left-sided), pancreas, prostate — the appeal must include a photon-vs-proton comparison plan with DVH overlay. The decisive question is whether the photon plan exceeds QUANTEC OAR constraints. Document mean heart dose, LAD V40, lung V20 / V5, contralateral breast dose, hippocampus D40%, brainstem Dmax, optic apparatus Dmax, cochlea Dmax, and (for re-irradiation) cumulative spinal cord EQD2.

Two trials anchor the proton-vs-photon argument for Group 2:

• Bekelman JAMA 2022 (RTOG 1308) — randomized proton vs IMRT for esophageal, NSCLC, and head and neck. Disease control comparable with reduced acute G3+ toxicity in elderly esophageal cohort. Primary on-point trial for adult proton in thoracic and upper-GI sites.
• PARTIQoL / NRG-GU006 — proton vs IMRT for prostate; primary endpoint patient-reported bowel quality of life non-inferior; long-term outcomes pending. Useful when proton is requested for prostate based on patient-specific GI risk.

For pediatric proton, the Pediatric Proton/Photon Consortium Registry (PORO) and COG-protocol mandates make the appeal nearly automatic — every major pediatric solid-tumor protocol prefers proton when CNS or developing OARs would be over-irradiated by photon.

Prostate SBRT: PACE-B and HYPO-RT-PC ended the debate

If you are still seeing denials for prostate SBRT in 2026, it is almost always a documentation issue, not a policy issue. The two trials that define current standard:

• PACE-B (Tree Lancet Oncol 2022) — SBRT 36.25 Gy / 5 fx non-inferior to conventional or moderately hypofractionated EBRT for low-risk and favorable-intermediate-risk prostate at 5-year biochemical / clinical failure; GU and GI toxicity comparable.
• HYPO-RT-PC (Widmark Lancet 2019) — ultra-hypofractionated 42.7 Gy / 7 fx non-inferior to conventional 78 Gy / 39 fx for intermediate / high-risk prostate at 5 years.

The controlling consensus is the ASTRO/ASCO/AUA Hypofractionated Radiation for Localized Prostate Cancer Guideline (Morgan JCO 2018, 2024 update incorporating ultra-hypofractionation / SBRT). A successful prostate SBRT appeal contains:

• Explicit NCCN risk-group documentation (low / favorable-intermediate / unfavorable-intermediate / high / very-high) with PSA, Gleason / ISUP grade group, clinical T-stage, percent positive cores, and Decipher when available.
• Fractionation matching guideline-supported ranges (36.25 Gy / 5 fx is the most-cited).
• Disease-site GU tumor board note with consensus modality recommendation.
• ICD-10 (C61) and CPT 77373 (SBRT delivery) explicitly stated.
• Citation of PACE-B + HYPO-RT-PC + ASTRO/ASCO/AUA Guideline by name.

When the denial cites Aetna or Cigna SBRT prostate policy language verbatim, the appeal quotes the policy back, lists the criteria met, and attaches the trial citations.

Lung SBRT: STARS and the operability question

For early-stage NSCLC, lung SBRT is broadly covered but appeals still arise when:

• The patient is operable and the insurer asks why surgery wasn't offered.
• The lesion is centrally located and SBRT carries higher toxicity risk.
• Multiple metastatic lesions are being treated under an oligometastatic indication.

STARS (Chang Lancet Oncol 2015) and the revised STARS analysis (Welsh JTO 2024) address operability — SBRT was non-inferior or superior in OS to lobectomy in selected operable patients. SABR-COMET (Palma Lancet 2019) establishes SBRT for ≤5 oligometastatic lesions vs standard of care, with OS benefit. ESTRO/EORTC oligometastatic consensus (Lievens Radiother Oncol 2020) defines the disease state. NCCN endorses metastasis-directed therapy in selected histologies (NSCLC, prostate, breast, colorectal, sarcoma).

A successful lung-SBRT-for-oligomets appeal documents the lesion count, primary site, prior systemic therapy, performance status, and the multidisciplinary tumor-board recommendation.

Brachytherapy: ABS Consensus and ASCENDE-RT

Brachytherapy denials are usually for high-risk prostate LDR boost combined with EBRT or for APBI brachytherapy in early breast cancer. The defining trial:

ASCENDE-RT (Morris IJROBP 2017) randomized high-risk prostate patients to dose-escalated EBRT alone vs EBRT plus LDR brachytherapy boost. The brachytherapy boost arm had superior biochemical progression-free survival at long-term follow-up. NCCN endorses brachytherapy boost for unfavorable-intermediate and high-risk prostate.

Quote the American Brachytherapy Society (ABS) Consensus Statements by name:

• ABS Consensus on Prostate LDR Brachytherapy
• ABS Consensus on Prostate HDR Brachytherapy
• ABS Consensus on Breast APBI Brachytherapy
• ABS Consensus on GYN Brachytherapy

For GYN brachytherapy, particularly definitive cervical cancer, omission of intracavitary or interstitial brachytherapy is below NCCN standard of care. NCCN Cervical Cancer Guidelines explicitly mandate brachytherapy boost; an EBRT-only plan is not acceptable for definitive intent.

IMRT escalation: the DVH wins the argument

When an insurer denies IMRT in favor of 3D-CRT, the appeal must include a comparative DVH showing 3D-CRT exceeds QUANTEC OAR constraints. Typical violations:

• Head and neck: parotid mean > 26 Gy, contralateral parotid > 20 Gy, larynx mean > 45 Gy.
• Prostate: rectum V70 > 20%, bladder V65 > 30%.
• Anal canal / GYN: small bowel V45 > 195 cc.
• CNS: brainstem Dmax > 54 Gy, optic apparatus > 54 Gy, cochlea Dmax > 45 Gy.
• Lung / mediastinum: lung V20 > 35%, heart mean > 26 Gy.

ASTRO disease-site CPGs (head and neck, prostate, anal cancer, GYN, CNS) endorse IMRT in these settings; many insurer policies require only that DVH comparison establish 3D-CRT cannot meet constraints. Submit it.

Re-irradiation: cumulative EQD2 and the consensus thresholds

Re-irradiation is the single trickiest appeal because the toxicity calculus is patient-specific. The framework:

• Convert prior dose to EQD2 (equivalent dose in 2-Gy fractions) using the linear-quadratic model with α/β = 3 for late-responding tissues.
• Add the proposed re-RT EQD2.
• Compare cumulative EQD2 to consensus OAR thresholds.

Authoritative documents:

• AAPM TG-101 (Benedict Med Phys 2010) — SBRT physics and OAR constraints.
• Andratschke Radiother Oncol 2022 — spine re-irradiation consensus.
• NRG-BR002 / NRG-LU007 — re-RT trial frameworks.

The appeal letter explicitly states prior treatment date, prior dose / fractionation / volume, cumulative EQD2 to spinal cord (typical re-RT threshold 50–55 Gy with adequate interval), brainstem, optic apparatus, lung, heart, bladder, rectum. Document time interval since prior RT (most consensus statements require ≥6 months, often longer for cord).

IORT and APBI: TARGIT-A and ELIOT

For breast intra-operative radiation therapy (IORT) and accelerated partial-breast irradiation (APBI), two trials anchor the appeal:

• TARGIT-A long-term (Vaidya BMJ 2020) — single-fraction IORT non-inferior to whole-breast EBRT for selected low-risk early breast cancer.
• ELIOT (Veronesi Lancet Oncol 2013) — full-dose electron IORT in early breast cancer.

The ASTRO APBI Consensus Statement (Smith PRO 2018; 2023 update) lists IORT as an acceptable APBI option for selected low-risk patients. The appeal identifies suitability criteria (age ≥50, T1, N0, ER+, ductal histology, negative margins, no LVI) and cites the consensus.

MRI-LINAC adaptive RT: the on-table replanning argument

MRI-LINAC (Elekta Unity, ViewRay MRIdian) denials cite "duplicative of CBCT-IGRT" or "not medically necessary." The clinical case for MRI-LINAC rests on real-time soft-tissue tracking and on-table adaptive replanning — neither of which CBCT-IGRT can do.

The trial that anchors pancreas adaptive: SMART (Parikh PRO 2023) — stereotactic MR-guided adaptive RT for borderline-resectable / locally-advanced pancreas; reduced GI toxicity at dose-escalated levels. Other on-point sites: liver, prostate with daily anatomic change, GYN with bladder / rectum filling variability, lung tumors with respiratory motion.

The appeal cites:

• ASTRO + AAPM TG-264 (MRI-guided RT QA program).
• SMART pancreas (Parikh PRO 2023).
• Site-specific rationale: daily anatomic change documented on prior imaging, OARs that shift with respiration / filling, dose escalation that requires real-time tracking.

NCCN, the universal anchor

NCCN Clinical Practice Guidelines apply to almost every denial in radiation oncology. Always cite the specific disease-site guideline by name and version (e.g., "NCCN Prostate Cancer v2.2026"). The insurer's medical-necessity reviewer is supposed to follow NCCN as a baseline; departures must be justified.

For dosimetric and physics constraints, QUANTEC (Quantitative Analysis of Normal Tissue Effects in the Clinic, IJROBP 2010 supplement) remains the most-cited reference for OAR thresholds.

Tumor board: the document that turns close calls

A disease-site multidisciplinary tumor-board note is the single highest-leverage piece of documentation in a radiation-oncology appeal. It establishes:

• Multispecialty consensus (rad onc + med onc + surgery + radiology + pathology).
• Modality choice rationale.
• NCCN-aligned recommendation.
• Date of review.

Many insurer policies explicitly require it for proton, stereotactic, and brachytherapy. Practices that hold disease-site tumor boards weekly should be capturing the consensus in the EHR with attendees, recommendation, and rationale — and submitting it as the lead exhibit on appeal.

The peer-to-peer call

Most radiation-oncology denials carry a peer-to-peer deadline (often 14 days) with the insurer's medical director. Demand it explicitly in the appeal letter. Rules:

• The reviewer must be same-specialty — a board-certified radiation oncologist, not a medical oncologist or general physician.
• Bring the comparative dosimetry, the tumor-board note, and the named guideline citation.
• Document who you spoke to and the outcome.

A peer-to-peer reviewed by a same-specialty radiation oncologist often overturns the denial without a written appeal. Even if it doesn't, the call generates a paper trail strengthening the next-level review.

Letter length and tone

A radiation-oncology appeal should be 1.5 to 2 pages — long enough to address the denial point-by-point and attach the dosimetry, short enough that the medical director will read it. Structure:

1. Header — member ID, claim #, modality, CPT, ICD-10.

2. Diagnosis + AJCC stage + biomarkers (PSA, Decipher, OncotypeDx, EGFR/ALK, MGMT, IDH, hormone receptors).

3. NCCN-aligned modality rationale (cite version).

4. Comparative dosimetry summary (where applicable) — photon vs proton or 3D vs IMRT or photon vs SBRT, with QUANTEC-referenced OAR constraints.

5. Address denial reason directly — quote insurer's own coverage criteria, demonstrate each is met, cite ASTRO Model Policy / ASTRO CPG / NCCN / pivotal trial.

6. Closing — request overturn within deadline, demand peer-to-peer with same-specialty radiation oncologist.

Tone is professional, firm, evidence-driven. Avoid emotional or sales language; the reviewer responds to citations and DVH numbers.

When to escalate

If first-level appeal fails:

• Self-funded ERISA plans — second-level internal appeal, then external review (binding under ACA §2719).
• Fully-insured / state-regulated plans — state-mandated external review.
• Medicare Advantage — Independent Review Entity (IRE), then ALJ hearing.
• Medicaid — state Fair Hearing.

Each level has its own deadline (usually 60–180 days). For radiation oncology specifically, expedited review is appropriate when treatment delay would compromise oncologic outcome — document the time-sensitive nature of the diagnosis (e.g., locally advanced cervical cancer, glioblastoma, pancreatic ca, head and neck) and request expedited determination.

What good looks like

A successful radiation-oncology appeal:

• Quotes the insurer's own policy (proton, SBRT, brachytherapy, IMRT, IORT, MRI-LINAC) by name and policy number.
• Cites ASTRO Model Policy + ASTRO CPG + NCCN (named version) + ABS Consensus + AAPM TG report + pivotal trial (PACE-B, HYPO-RT-PC, ASCENDE-RT, STARS, SABR-COMET, PARTIQoL, Bekelman JAMA 2022, TARGIT-A, ELIOT, SMART) by name.
• Includes comparative dosimetry with DVH overlays and QUANTEC-referenced OAR constraints.
• References tumor-board consensus by date and attendees.
• Documents NCCN risk group, AJCC stage, biomarkers, and CPT.
• Demands peer-to-peer with same-specialty radiation oncologist.
• Stays within 2 pages.

Most modality denials reverse on first appeal when the comparative dosimetry, the tumor-board note, and the named guideline citation are in the file. The work is in the documentation — once the chart contains the right numbers, drafting the letter is mechanical.